NCT00733122 2025-03-03
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
Clinical Trials
6 trialsNCT05316064 2024-05-10
Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic
Universiti Sains Malaysia
Phase 2/3 Withdrawn
NCT04044950 2020-09-22
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03887793 2020-02-26
Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination in Integrated Healthcare Delivery Systems
University of North Carolina, Chapel Hill
Phase NA Withdrawn
NCT02082639 2015-07-20
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years
GlaxoSmithKline
Phase 3 Withdrawn
NCT02100618 2015-07-20
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
GlaxoSmithKline
Phase 3 Withdrawn